Treatment of HCV infection by targeting microRNA.

By H. Janssen, H. Reesink, E. Lawitz, S. Zeuzem, M. Rodríguez-Torres, K. Patel, A. J. van der Meer, A. Patick, Alice Chen, Yi Zhou and 5 more. New England Journal of Medicine, 2013

2,154 citations recorded by the source corpus.

Subfields: Cancer Research, Hepatology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/3bb679e731d50dd567d0c601896cfa84b89fdcee

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Hepatology

T. Baumert

In Molecular Biology

Citations in the corpus

OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer (2016, positive): “Despite its antitumoral properties, miR-122 is also known to stabilize HCV RNA by binding to the 50-untranslated region, thereby promoting HCV replication (27).”
Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation (2015, background): “Therapeutic oligonucleotides (ONs) including antisense oligodeoxynucleotides (ODNs), small interfering RNAs (siRNAs), and the more recently discovered micro RNAs (miRNAs) designed for targeted inhibition of specific mRNA sequences are of emerging interest for the treatment and diagnosis of cancer [1”
Development of microRNA therapeutics is coming of age (2014, neutral): “Furthermore, data from the first phase 2 study with miravirsen in HCV-infected patients were recently published (Janssen et al , 2013).”
Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. (2014, positive): “Nota-bly, several miRNA-based therapeutics are used in clinical trials, including antagomir (inhibitor) against miR-122 for hepatitis treatment, which is in phase 2 clinical trials (48), or miRNA mimic for miR-34 to treat cancer, which is in preclinical development (49).”
The delivery of therapeutic oligonucleotides (2016, background): “Some examples might include a use of a receptor-targeted siRNA conjugate (5), strong effects on liver diseases using antisense with novel chemical modifications (6,7), anti-cancer effects with a miRNA (8) and treatment of a neurodegenerative disease via intrathecal administration of a SSO (9).”
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine (2017, background): “Miravirsen and Santaris Pharma Miravirsen is an LNA-modified DNA phosphorothioate antisense oligonucleotide (ASO) that inhibits miR-122.(52,53) This is the first miRNA-targeted drug to enter phase II clinical trials to understand its safety and tolerability in the patients; this drug is sponsored by”